Poorly soluble APIs now represent the majority of the pharmaceutical development pipeline. Dissolution and oral bioavailability are determined by molecular solubility, surface wetting behavior, solid-state stability, and how the formulation interacts with the GI environment from first contact onward. Amorphous dispersions, lipid systems, nanocrystals, and co-crystals each rely on different surface mechanisms to deliver their intended advantage.
